Search

Your search keyword '"Lombardi D."' showing total 582 results
Start Over Author "Lombardi D." Search Limiters Full Text
582 results on '"Lombardi D."'

2. Event Generators for High-Energy Physics Experiments

Author

Campbell, J. M., Diefenthaler, M., Hobbs, T. J., Höche, S., Isaacson, J., Kling, F., Mrenna, S., Reuter, J., Alioli, S., Andersen, J. R., Andreopoulos, C., Ankowski, A. M., Aschenauer, E. C., Ashkenazi, A., Baker, M. D., Barrow, J. L., van Beekveld, M., Bewick, G., Bhattacharya, S., Bierlich, C., Bothmann, E., Bredt, P., Broggio, A., Buckley, A., Butter, A., Butterworth, J. M., Byrne, E. P., Calame, C. M. Carloni, Chakraborty, S., Chen, X., Chiesa, M., Childers, J. T., Cruz-Martinez, J., Currie, J., Darvishi, N., Dasgupta, M., Denner, A., Dreyer, F. A., Dytman, S., El-Menoufi, B. K., Engel, T., Ravasio, S. Ferrario, Figueroa, D., Flower, L., Forshaw, J. R., Frederix, R., Friedland, A., Frixione, S., Gallagher, H., Gallmeister, K., Gardiner, S., Gauld, R., Gaunt, J., Gavardi, A., Gehrmann, T., Ridder, A. Gehrmann-De, Gellersen, L., Giele, W., Gieseke, S., Giuli, F., Glover, E. W. N., Grazzini, M., Grohsjean, A., Gütschow, C., Hamilton, K., Han, T., Hatcher, R., Heinrich, G., Helenius, I., Hen, O., Hirschi, V., Höfer, M., Holguin, J., Huss, A., Ilten, P., Jadach, S., Jentsch, A., Jones, S. P., Ju, W., Kallweit, S., Karlberg, A., Katori, T., Kerner, M., Kilian, W., Kirchgaeßer, M. M., Klein, S., Knobbe, M., Krause, C., Krauss, F., Lang, J., Lang, J. -N., Lee, G., Li, S. W., Lim, M. A., Lindert, J. M., Lombardi, D., Lönnblad, L., Löschner, M., Lurkin, N., Ma, Y., Machado, P., Magerya, V., Maier, A., Majer, I., Maltoni, F., Marcoli, M., Marinelli, G., Masouminia, M. R., Mastrolia, P., Mattelaer, O., Mazzitelli, J., McFayden, J., Medves, R., Meinzinger, P., Mo, J., Monni, P. F., Montagna, G., Morgan, T., Mosel, U., Nachman, B., Nadolsky, P., Nagar, R., Nagy, Z., Napoletano, D., Nason, P., Neumann, T., Nevay, L. J., Nicrosini, O., Niehues, J., Niewczas, K., Ohl, T., Ossola, G., Pandey, V., Papadopoulou, A., Papaefstathiou, A., Paz, G., Pellen, M., Pelliccioli, G., Peraro, T., Piccinini, F., Pickering, L., Pires, J., Płaczek, W., Plätzer, S., Plehn, T., Pozzorini, S., Prestel, S., Preuss, C. T., Price, A. C., Quackenbush, S., Re, E., Reichelt, D., Reina, L., Reuschle, C., Richardson, P., Rocco, M., Rocco, N., Roda, M., Garcia, A. Rodriguez, Roiser, S., Rojo, J., Rottoli, L., Salam, G. P., Schönherr, M., Schuchmann, S., Schumann, S., Schürmann, R., Scyboz, L., Seymour, M. H., Siegert, F., Signer, A., Chahal, G. Singh, Siódmok, A., Sjöstrand, T., Skands, P., Smillie, J. M., Sobczyk, J. T., Soldin, D., Soper, D. E., Soto-Ontoso, A., Soyez, G., Stagnitto, G., Tena-Vidal, J., Tomalak, O., Tramontano, F., Trojanowski, S., Tu, Z., Uccirati, S., Ullrich, T., Ulrich, Y., Utheim, M., Valassi, A., Verbytskyi, A., Verheyen, R., Wagman, M., Walker, D., Webber, B. R., Weinstein, L., White, O., Whitehead, J., Wiesemann, M., Wilkinson, C., Williams, C., Winterhalder, R., Wret, C., Xie, K., Yang, T-Z., Yazgan, E., Zanderighi, G., Zanoli, S., and Zapp, K.

Subjects
High Energy Physics - Phenomenology, High Energy Physics - Experiment
Abstract

We provide an overview of the status of Monte-Carlo event generators for high-energy particle physics. Guided by the experimental needs and requirements, we highlight areas of active development, and opportunities for future improvements. Particular emphasis is given to physics models and algorithms that are employed across a variety of experiments. These common themes in event generator development lead to a more comprehensive understanding of physics at the highest energies and intensities, and allow models to be tested against a wealth of data that have been accumulated over the past decades. A cohesive approach to event generator development will allow these models to be further improved and systematic uncertainties to be reduced, directly contributing to future experimental success. Event generators are part of a much larger ecosystem of computational tools. They typically involve a number of unknown model parameters that must be tuned to experimental data, while maintaining the integrity of the underlying physics models. Making both these data, and the analyses with which they have been obtained accessible to future users is an essential aspect of open science and data preservation. It ensures the consistency of physics models across a variety of experiments., Comment: 164 pages, 10 figures, contribution to Snowmass 2021

Published
2022

3. Nonlinear model reduction on metric spaces. Application to one-dimensional conservative PDEs in Wasserstein spaces

Author

Ehrlacher, V., Lombardi, D., Mula, O., and Vialard, F. -X.

Subjects
Mathematics - Numerical Analysis
Abstract

We consider the problem of model reduction of parametrized PDEs where the goal is to approximate any function belonging to the set of solutions at a reduced computational cost. For this, the bottom line of most strategies has so far been based on the approximation of the solution set by linear spaces on Hilbert or Banach spaces. This approach can be expected to be successful only when the Kolmogorov width of the set decays fast. While this is the case on certain parabolic or elliptic problems, most transport-dominated problems are expected to present a slow decaying width and require to study nonlinear approximation methods. In this work, we propose to address the reduction problem from the perspective of general metric spaces with a suitably defined notion of distance. We develop and compare two different approaches, one based on barycenters and another one using tangent spaces when the metric space has an additional Riemannian structure. As a consequence of working in metric spaces, both approaches are automatically nonlinear. We give theoretical and numerical evidence of their efficiency to reduce complexity for one-dimensional conservative PDEs where the underlying metric space can be chosen to be the $L^2$-Wasserstein space.

Published
2019

4. Event generators for high-energy physics experiments

Author

Campbell, J, Diefenthaler, M, Hobbs, T, Hoche, S, Isaacson, J, Kling, F, Mrenna, S, Reuter, J, Alioli, S, Andersen, J, Andreopoulos, C, Ankowski, A, Aschenauer, E, Ashkenazi, A, Baker, M, Barrow, J, van Beekveld, M, Bewick, G, Bhattacharya, S, Bierlich, C, Bothmann, E, Bredt, P, Broggio, A, Buckley, A, Butter, A, Butterworth, J, Byrne, E, Calame, C, Chakraborty, S, Chen, X, Chiesa, M, Childers, J, Cruz-Martinez, J, Currie, J, Darvishi, N, Dasgupta, M, Denner, A, Dreyer, F, Dytman, S, El-Menoufi, B, Engel, T, Ravasio, S, Figueroa, D, Flower, L, Forshaw, J, Frederix, R, Friedland, A, Frixione, S, Gallagher, H, Gallmeister, K, Gardiner, S, Gauld, R, Gaunt, J, Gavardi, A, Gehrmann, T, De Ridder, A, Gellersen, L, Giele, W, Gieseke, S, Giuli, F, Glover, E, Grazzini, M, Grohsjean, A, Gutschow, C, Hamilton, K, Han, T, Hatcher, R, Heinrich, G, Helenius, I, Hen, O, Hirschi, V, Hofer, M, Holguin, J, Huss, A, Ilten, P, Jadach, S, Jentsch, A, Jones, S, Ju, W, Kallweit, S, Karlberg, A, Katori, T, Kerner, M, Kilian, W, Kirchgaesser, M, Klein, S, Knobbe, M, Krause, C, Krauss, F, Lang, J, Lee, G, Li, S, Lim, M, Lindert, J, Lombardi, D, Lonnblad, L, Loschner, M, Lurkin, N, Ma, Y, Machado, P, Magerya, V, Maier, A, Majer, I, Maltoni, F, Marcoli, M, Marinelli, G, Masouminia, M, Mastrolia, P, Mattelaer, O, Mazzitelli, J, Mcfayden, J, Medves, R, Meinzinger, P, Mo, J, Monni, P, Montagna, G, Morgan, T, Mosel, U, Nachman, B, Nadolsky, P, Nagar, R, Nagy, Z, Napoletano, D, Nason, P, Neumann, T, Nevay, L, Nicrosini, O, Niehues, J, Niewczas, K, Ohl, T, Ossola, G, Pandey, V, Papadopoulou, A, Papaefstathiou, A, Paz, G, Pellen, M, Pelliccioli, G, Peraro, T, Piccinini, F, Pickering, L, Pires, J, Placzek, W, Platzer, S, Plehn, T, Pozzorini, S, Prestel, S, Preuss, C, Price, A, Quackenbush, S, Re, E, Reichelt, D, Reina, L, Reuschle, C, Richardson, P, Rocco, M, Rocco, N, Roda, M, Garcia, A, Roiser, S, Rojo, J, Rottoli, L, Salam, G, Schonherr, M, Schuchmann, S, Schumann, S, Schurmann, R, Scyboz, L, Seymour, M, Siegert, F, Signer, A, Chahal, G, Siodmok, A, Sjostrand, T, Skands, P, Smillie, J, Sobczyk, J, Soldin, D, Soper, D, Soto-Ontoso, A, Soyez, G, Stagnitto, G, Tena-Vidal, J, Tomalak, O, Tramontano, F, Trojanowski, S, Tu, Z, Uccirati, S, Ullrich, T, Ulrich, Y, Utheim, M, Valassi, A, Verbytskyi, A, Verheyen, R, Wagman, M, Walker, D, Webber, B, Weinstein, L, White, O, Whitehead, J, Wiesemann, M, Wilkinson, C, Williams, C, Winterhalder, R, Wret, C, Xie, K, Yang, T, Yazgan, E, Zanderighi, G, Zanoli, S, Zapp, K, Campbell J. M., Diefenthaler M., Hobbs T. J., Hoche S., Isaacson J., Kling F., Mrenna S., Reuter J., Alioli S., Andersen J. R., Andreopoulos C., Ankowski A. M., Aschenauer E. C., Ashkenazi A., Baker M. D., Barrow J. L., van Beekveld M., Bewick G., Bhattacharya S., Bierlich C., Bothmann E., Bredt P., Broggio A., Buckley A., Butter A., Butterworth J. M., Byrne E. P., Calame C. M. C., Chakraborty S., Chen X., Chiesa M., Childers J. T., Cruz-Martinez J., Currie J., Darvishi N., Dasgupta M., Denner A., Dreyer F. A., Dytman S., El-Menoufi B. K., Engel T., Ravasio S. F., Figueroa D., Flower L., Forshaw J. R., Frederix R., Friedland A., Frixione S., Gallagher H., Gallmeister K., Gardiner S., Gauld R., Gaunt J., Gavardi A., Gehrmann T., De Ridder A. G., Gellersen L., Giele W., Gieseke S., Giuli F., Glover E. W. N., Grazzini M., Grohsjean A., Gutschow C., Hamilton K., Han T., Hatcher R., Heinrich G., Helenius I., Hen O., Hirschi V., Hofer M., Holguin J., Huss A., Ilten P., Jadach S., Jentsch A., Jones S. P., Ju W., Kallweit S., Karlberg A., Katori T., Kerner M., Kilian W., Kirchgaesser M. M., Klein S., Knobbe M., Krause C., Krauss F., Lang J., Lang J. -N., Lee G., Li S. W., Lim M. A., Lindert J. M., Lombardi D., Lonnblad L., Loschner M., Lurkin N., Ma Y., Machado P., Magerya V., Maier A., Majer I., Maltoni F., Marcoli M., Marinelli G., Masouminia M. R., Mastrolia P., Mattelaer O., Mazzitelli J., McFayden J., Medves R., Meinzinger P., Mo J., Monni P. F., Montagna G., Morgan T., Mosel U., Nachman B., Nadolsky P., Nagar R., Nagy Z., Napoletano D., Nason P., Neumann T., Nevay L. J., Nicrosini O., Niehues J., Niewczas K., Ohl T., Ossola G., Pandey V., Papadopoulou A., Papaefstathiou A., Paz G., Pellen M., Pelliccioli G., Peraro T., Piccinini F., Pickering L., Pires J., Placzek W., Platzer S., Plehn T., Pozzorini S., Prestel S., Preuss C. T., Price A. C., Quackenbush S., Re E., Reichelt D., Reina L., Reuschle C., Richardson P., Rocco M., Rocco N., Roda M., Garcia A. R., Roiser S., Rojo J., Rottoli L., Salam G. P., Schonherr M., Schuchmann S., Schumann S., Schurmann R., Scyboz L., Seymour M. H., Siegert F., Signer A., Chahal G. S., Siodmok A., Sjostrand T., Skands P., Smillie J. M., Sobczyk J. T., Soldin D., Soper D. E., Soto-Ontoso A., Soyez G., Stagnitto G., Tena-Vidal J., Tomalak O., Tramontano F., Trojanowski S., Tu Z., Uccirati S., Ullrich T., Ulrich Y., Utheim M., Valassi A., Verbytskyi A., Verheyen R., Wagman M., Walker D., Webber B. R., Weinstein L., White O., Whitehead J., Wiesemann M., Wilkinson C., Williams C., Winterhalder R., Wret C., Xie K., Yang T. -Z., Yazgan E., Zanderighi G., Zanoli S., Zapp K., Campbell, J, Diefenthaler, M, Hobbs, T, Hoche, S, Isaacson, J, Kling, F, Mrenna, S, Reuter, J, Alioli, S, Andersen, J, Andreopoulos, C, Ankowski, A, Aschenauer, E, Ashkenazi, A, Baker, M, Barrow, J, van Beekveld, M, Bewick, G, Bhattacharya, S, Bierlich, C, Bothmann, E, Bredt, P, Broggio, A, Buckley, A, Butter, A, Butterworth, J, Byrne, E, Calame, C, Chakraborty, S, Chen, X, Chiesa, M, Childers, J, Cruz-Martinez, J, Currie, J, Darvishi, N, Dasgupta, M, Denner, A, Dreyer, F, Dytman, S, El-Menoufi, B, Engel, T, Ravasio, S, Figueroa, D, Flower, L, Forshaw, J, Frederix, R, Friedland, A, Frixione, S, Gallagher, H, Gallmeister, K, Gardiner, S, Gauld, R, Gaunt, J, Gavardi, A, Gehrmann, T, De Ridder, A, Gellersen, L, Giele, W, Gieseke, S, Giuli, F, Glover, E, Grazzini, M, Grohsjean, A, Gutschow, C, Hamilton, K, Han, T, Hatcher, R, Heinrich, G, Helenius, I, Hen, O, Hirschi, V, Hofer, M, Holguin, J, Huss, A, Ilten, P, Jadach, S, Jentsch, A, Jones, S, Ju, W, Kallweit, S, Karlberg, A, Katori, T, Kerner, M, Kilian, W, Kirchgaesser, M, Klein, S, Knobbe, M, Krause, C, Krauss, F, Lang, J, Lee, G, Li, S, Lim, M, Lindert, J, Lombardi, D, Lonnblad, L, Loschner, M, Lurkin, N, Ma, Y, Machado, P, Magerya, V, Maier, A, Majer, I, Maltoni, F, Marcoli, M, Marinelli, G, Masouminia, M, Mastrolia, P, Mattelaer, O, Mazzitelli, J, Mcfayden, J, Medves, R, Meinzinger, P, Mo, J, Monni, P, Montagna, G, Morgan, T, Mosel, U, Nachman, B, Nadolsky, P, Nagar, R, Nagy, Z, Napoletano, D, Nason, P, Neumann, T, Nevay, L, Nicrosini, O, Niehues, J, Niewczas, K, Ohl, T, Ossola, G, Pandey, V, Papadopoulou, A, Papaefstathiou, A, Paz, G, Pellen, M, Pelliccioli, G, Peraro, T, Piccinini, F, Pickering, L, Pires, J, Placzek, W, Platzer, S, Plehn, T, Pozzorini, S, Prestel, S, Preuss, C, Price, A, Quackenbush, S, Re, E, Reichelt, D, Reina, L, Reuschle, C, Richardson, P, Rocco, M, Rocco, N, Roda, M, Garcia, A, Roiser, S, Rojo, J, Rottoli, L, Salam, G, Schonherr, M, Schuchmann, S, Schumann, S, Schurmann, R, Scyboz, L, Seymour, M, Siegert, F, Signer, A, Chahal, G, Siodmok, A, Sjostrand, T, Skands, P, Smillie, J, Sobczyk, J, Soldin, D, Soper, D, Soto-Ontoso, A, Soyez, G, Stagnitto, G, Tena-Vidal, J, Tomalak, O, Tramontano, F, Trojanowski, S, Tu, Z, Uccirati, S, Ullrich, T, Ulrich, Y, Utheim, M, Valassi, A, Verbytskyi, A, Verheyen, R, Wagman, M, Walker, D, Webber, B, Weinstein, L, White, O, Whitehead, J, Wiesemann, M, Wilkinson, C, Williams, C, Winterhalder, R, Wret, C, Xie, K, Yang, T, Yazgan, E, Zanderighi, G, Zanoli, S, Zapp, K, Campbell J. M., Diefenthaler M., Hobbs T. J., Hoche S., Isaacson J., Kling F., Mrenna S., Reuter J., Alioli S., Andersen J. R., Andreopoulos C., Ankowski A. M., Aschenauer E. C., Ashkenazi A., Baker M. D., Barrow J. L., van Beekveld M., Bewick G., Bhattacharya S., Bierlich C., Bothmann E., Bredt P., Broggio A., Buckley A., Butter A., Butterworth J. M., Byrne E. P., Calame C. M. C., Chakraborty S., Chen X., Chiesa M., Childers J. T., Cruz-Martinez J., Currie J., Darvishi N., Dasgupta M., Denner A., Dreyer F. A., Dytman S., El-Menoufi B. K., Engel T., Ravasio S. F., Figueroa D., Flower L., Forshaw J. R., Frederix R., Friedland A., Frixione S., Gallagher H., Gallmeister K., Gardiner S., Gauld R., Gaunt J., Gavardi A., Gehrmann T., De Ridder A. G., Gellersen L., Giele W., Gieseke S., Giuli F., Glover E. W. N., Grazzini M., Grohsjean A., Gutschow C., Hamilton K., Han T., Hatcher R., Heinrich G., Helenius I., Hen O., Hirschi V., Hofer M., Holguin J., Huss A., Ilten P., Jadach S., Jentsch A., Jones S. P., Ju W., Kallweit S., Karlberg A., Katori T., Kerner M., Kilian W., Kirchgaesser M. M., Klein S., Knobbe M., Krause C., Krauss F., Lang J., Lang J. -N., Lee G., Li S. W., Lim M. A., Lindert J. M., Lombardi D., Lonnblad L., Loschner M., Lurkin N., Ma Y., Machado P., Magerya V., Maier A., Majer I., Maltoni F., Marcoli M., Marinelli G., Masouminia M. R., Mastrolia P., Mattelaer O., Mazzitelli J., McFayden J., Medves R., Meinzinger P., Mo J., Monni P. F., Montagna G., Morgan T., Mosel U., Nachman B., Nadolsky P., Nagar R., Nagy Z., Napoletano D., Nason P., Neumann T., Nevay L. J., Nicrosini O., Niehues J., Niewczas K., Ohl T., Ossola G., Pandey V., Papadopoulou A., Papaefstathiou A., Paz G., Pellen M., Pelliccioli G., Peraro T., Piccinini F., Pickering L., Pires J., Placzek W., Platzer S., Plehn T., Pozzorini S., Prestel S., Preuss C. T., Price A. C., Quackenbush S., Re E., Reichelt D., Reina L., Reuschle C., Richardson P., Rocco M., Rocco N., Roda M., Garcia A. R., Roiser S., Rojo J., Rottoli L., Salam G. P., Schonherr M., Schuchmann S., Schumann S., Schurmann R., Scyboz L., Seymour M. H., Siegert F., Signer A., Chahal G. S., Siodmok A., Sjostrand T., Skands P., Smillie J. M., Sobczyk J. T., Soldin D., Soper D. E., Soto-Ontoso A., Soyez G., Stagnitto G., Tena-Vidal J., Tomalak O., Tramontano F., Trojanowski S., Tu Z., Uccirati S., Ullrich T., Ulrich Y., Utheim M., Valassi A., Verbytskyi A., Verheyen R., Wagman M., Walker D., Webber B. R., Weinstein L., White O., Whitehead J., Wiesemann M., Wilkinson C., Williams C., Winterhalder R., Wret C., Xie K., Yang T. -Z., Yazgan E., Zanderighi G., Zanoli S., and Zapp K.

Abstract

We provide an overview of the status of Monte-Carlo event generators for high-energy particle physics. Guided by the experimental needs and requirements, we highlight areas of active development, and opportunities for future improvements. Particular emphasis is given to physics models and algorithms that are employed across a variety of experiments. These common themes in event generator development lead to a more comprehensive understanding of physics at the highest energies and intensities, and allow models to be tested against a wealth of data that have been accumulated over the past decades. A cohesive approach to event generator development will allow these models to be further improved and systematic uncertainties to be reduced, directly contributing to future experimental success. Event generators are part of a much larger ecosystem of computational tools. They typically involve a number of unknown model parameters that must be tuned to experimental data, while maintaining the integrity of the underlying physics models. Making both these data, and the analyses with which they have been obtained accessible to future users is an essential aspect of open science and data preservation. It ensures the consistency of physics models across a variety of experiments.

Published
2024

5. Event generators for high-energy physics experiments

Author

Campbell, J. M., primary, Diefenthaler, M., additional, Hobbs, T. J., additional, Höche, Stefan, additional, Isaacson, Joshua, additional, Kling, Felix, additional, Mrenna, Stephen, additional, Reuter, J., additional, Alioli, S., additional, Andersen, J. R., additional, Andreopoulos, C., additional, Ankowski, A. M., additional, Aschenauer, Elke Caroline, additional, Ashkenazi, A., additional, Baker, M. D., additional, Barrow, Joshua L., additional, van Beekveld, Melissa, additional, Bewick, Gavin, additional, Bhattacharya, S., additional, Bierlich, Christian, additional, Bothmann, Enrico, additional, Bredt, P., additional, Broggio, A., additional, Buckley, Andy, additional, Butter, A., additional, Butterworth, Jonathan Mark, additional, Byrne, E. P., additional, Carloni-Calame, Carlo, additional, Chakraborty, Smita, additional, Chen, X., additional, Chiesa, M., additional, Childers, J. T., additional, Cruz-Martinez, J., additional, Currie, J., additional, Darvishi, N., additional, Dasgupta, M., additional, Denner, A., additional, Dreyer, F. A., additional, Dytman, S., additional, El-Menoufi, Basem Kamal, additional, Engel, Tim, additional, Ferrario Ravasio, Silvia, additional, Figueroa, Daniel, additional, Flower, L., additional, Forshaw, J. R., additional, Frederix, Rikkert, additional, Friedland, Alex, additional, Frixione, Stefano, additional, Gallagher, H., additional, Gallmeister, K., additional, Gardiner, Simon, additional, Gauld, Rhorry, additional, Gaunt, Jonathan, additional, Gavardi, A., additional, Gehrmann, T., additional, Gehrmann-De Ridder, Aude, additional, Gellersen, Leif, additional, Giele, Walter, additional, Gieseke, Stefan, additional, Giuli, Francesco, additional, Glover, E. W. N., additional, Grazzini, Massimiliano, additional, Grohsjean, A., additional, Gütschow, Christian, additional, Hamilton, Keith, additional, Han, T., additional, Hatcher, R., additional, Heinrich, G., additional, Helenius, Ilkka, additional, Hen, O., additional, Hirschi, Valentin, additional, Höfer, M., additional, Holguin, J., additional, Huss, Alexander, additional, Ilten, Philip, additional, Jadach, Stanislaw, additional, Jentsch, A., additional, Jones, S. P., additional, Ju, W., additional, Kallweit, Stefan, additional, Karlberg, Alexander, additional, Katori, T., additional, Kerner, Matthias, additional, Kilian, C., additional, Kirchgaeßer, M. M., additional, Klein, S., additional, Knobbe, Max, additional, Krause, Claudius, additional, Krauss, Frank, additional, Lang, J., additional, Lang, J.-N, additional, Lee, G., additional, Li, S. W., additional, Lim, M. A., additional, Lindert, J. M., additional, Lombardi, D., additional, Lönnblad, Leif, additional, Löschner, M., additional, Lurkin, N., additional, Ma, Y., additional, Machado, P., additional, Magerya, Vitaly, additional, Maier, A., additional, Majer, I., additional, Maltoni, Fabio, additional, Marcoli, M., additional, Marinelli, G., additional, Masouminia, M. R., additional, Mastrolia, Pierpaolo, additional, Mattelaer, Olivier, additional, Mazzitelli, J., additional, McFayden, Josh, additional, Medves, Rok, additional, Meinzinger, P., additional, Mo, J., additional, Monni, Pier Francesco, additional, Montagna, Guido, additional, Morgan, T., additional, Mosel, U., additional, Nachman, Benjamin, additional, Nadolsky, Pavel, additional, Nagar, R., additional, Nagy, Zoltan, additional, Napoletano, Davide, additional, Nason, Paolo, additional, Neumann, Tobias, additional, Nevay, L. J., additional, Nicrosini, Oreste, additional, Niehues, J., additional, Niewczas, K., additional, Ohl, Thorsten, additional, Ossola, Giovanni, additional, Pandey, V., additional, Papadopoulou, A., additional, Papaefstathiou, Andreas, additional, Paz, Gil, additional, Pellen, Mathieu, additional, Pelliccioli, Giovanni, additional, Peraro, T., additional, Piccinini, Fluvio, additional, Pickering, L., additional, Pires, J., additional, Placzek, Wieslaw, additional, Plätzer, Simon, additional, Plehn, Tilman, additional, Pozzorini, Stefano, additional, Prestel, Stefan, additional, Preuss, Christian Tobias, additional, Price, A. C., additional, Quackenbush, Seth, additional, Re, Emanuele, additional, Reichelt, Daniel, additional, Reina, Laura, additional, Reuschle, Christian, additional, Richardson, Peter, additional, Rocco, M., additional, Rocco, N., additional, Roda, M., additional, Rodriguez Garcia, A., additional, Roiser, Stefan, additional, Rojo, Juan, additional, Rottoli, Luca, additional, Salam, Gavin P., additional, Schönherr, Marek, additional, Schuchmann, S., additional, Schumann, Steffen, additional, Schürmann, Robin, additional, Scyboz, Ludovic, additional, Seymour, Michael H., additional, Siegert, Frank, additional, Signer, Adrian, additional, Chahal, Gurpreet Singh, additional, Siódmok, Andrzej, additional, Sjöstrand, Torbjörn, additional, Skands, Peter, additional, Smillie, Jennifer M., additional, Sobczyk, J. T., additional, Soldin, Dennis, additional, Soper, D. E., additional, Soto-Ontoso, Alba, additional, Soyez, Gregory, additional, Stagnitto, Giovanni, additional, Tena-Vidal, J., additional, Tomalak, O., additional, Tramontano, Francesco, additional, Trojanowski, Sebastian, additional, Tu, Z., additional, Uccirati, Sandro, additional, Ullrich, T., additional, Ulrich, Yannick, additional, Utheim, Marius, additional, Valassi, A., additional, Verbytskyi, Andrii, additional, Verheyen, Rob, additional, Wagman, M., additional, Walker, D., additional, Webber, B. R., additional, Weinstein, L., additional, White, O., additional, Whitehead, James, additional, Wiesemann, Marius, additional, Wilkinson, C., additional, Williams, C., additional, Winterhalder, Ramon, additional, Wret, C., additional, Xie, K., additional, Yang, T.-Z., additional, Yazgan, E., additional, Zanderighi, Giulia, additional, Zanoli, S., additional, and Zapp, Korinna, additional

Published
2024
Full Text
View/download PDF

6. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

Author

Soria, A, Graziano, F, Ghilardi, G, Lapadula, G, Gasperina, D, Benatti, S, Quiros-Roldan, E, Milesi, M, Bai, F, Merli, M, Minisci, D, Franzetti, M, Asperges, E, Chiabrando, F, Pocaterra, D, Pandolfo, A, Zanini, F, Lombardi, D, Cappelletti, A, Rugova, A, Borghesi, M, Squillace, N, Pusterla, L, Piconi, S, Morelli, P, Querini, P, Bruno, R, Rusconi, S, Casari, S, Bandera, A, Franzetti, F, Travi, G, D'Arminio Monforte, A, Marchetti, G, Pan, A, Castelli, F, Rizzi, M, Dentali, F, Mallardo, M, Rossi, E, Valsecchi, M, Galimberti, S, Bonfanti, P, Soria, Alessandro, Graziano, Francesca, Ghilardi, Giulia, Lapadula, Giuseppe, Gasperina, Daniela Dalla, Benatti, Simone Vasilij, Quiros-Roldan, Eugenia, Milesi, Maurizio, Bai, Francesca, Merli, Marco, Minisci, Davide, Franzetti, Marco, Asperges, Erika, Chiabrando, Filippo, Pocaterra, Daria, Pandolfo, Alessandro, Zanini, Fabio, Lombardi, Domenico, Cappelletti, Anna, Rugova, Alban, Borghesi, Maria Lucia, Squillace, Nicola, Pusterla, Luigi, Piconi, Stefania, Morelli, Paola, Querini, Patrizia Rovere, Bruno, Raffaele, Rusconi, Stefano, Casari, Salvatore, Bandera, Alessandra, Franzetti, Fabio, Travi, Giovanna, D'Arminio Monforte, Antonella, Marchetti, Giulia, Pan, Angelo, Castelli, Francesco, Rizzi, Marco, Dentali, Francesco, Mallardo, Maria, Rossi, Emanuela, Valsecchi, Maria Grazia, Galimberti, Stefania, Bonfanti, Paolo, Soria, A, Graziano, F, Ghilardi, G, Lapadula, G, Gasperina, D, Benatti, S, Quiros-Roldan, E, Milesi, M, Bai, F, Merli, M, Minisci, D, Franzetti, M, Asperges, E, Chiabrando, F, Pocaterra, D, Pandolfo, A, Zanini, F, Lombardi, D, Cappelletti, A, Rugova, A, Borghesi, M, Squillace, N, Pusterla, L, Piconi, S, Morelli, P, Querini, P, Bruno, R, Rusconi, S, Casari, S, Bandera, A, Franzetti, F, Travi, G, D'Arminio Monforte, A, Marchetti, G, Pan, A, Castelli, F, Rizzi, M, Dentali, F, Mallardo, M, Rossi, E, Valsecchi, M, Galimberti, S, Bonfanti, P, Soria, Alessandro, Graziano, Francesca, Ghilardi, Giulia, Lapadula, Giuseppe, Gasperina, Daniela Dalla, Benatti, Simone Vasilij, Quiros-Roldan, Eugenia, Milesi, Maurizio, Bai, Francesca, Merli, Marco, Minisci, Davide, Franzetti, Marco, Asperges, Erika, Chiabrando, Filippo, Pocaterra, Daria, Pandolfo, Alessandro, Zanini, Fabio, Lombardi, Domenico, Cappelletti, Anna, Rugova, Alban, Borghesi, Maria Lucia, Squillace, Nicola, Pusterla, Luigi, Piconi, Stefania, Morelli, Paola, Querini, Patrizia Rovere, Bruno, Raffaele, Rusconi, Stefano, Casari, Salvatore, Bandera, Alessandra, Franzetti, Fabio, Travi, Giovanna, D'Arminio Monforte, Antonella, Marchetti, Giulia, Pan, Angelo, Castelli, Francesco, Rizzi, Marco, Dentali, Francesco, Mallardo, Maria, Rossi, Emanuela, Valsecchi, Maria Grazia, Galimberti, Stefania, and Bonfanti, Paolo

Abstract

Objective Monoclonal antibodies (mAbs) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) reduced Coronavirus Disease 2019 (COVID-19) hospitalizations in people at risk of clinical worsening. Real-world descriptions are limited. Methods CONDIVIDIAMO, a two-year multicenter observational study, consecutively enrolled SARS-CoV-2 outpatients with ≥1 risk factor for COVID-19 progression receiving mAbs. Demographic data, underlying medical condition, type of mAbs combination received, duration of symptoms before mAbs administration, COVID-19 vaccination history, were collected upon enrolment and centrally recorded. Data on outcomes (hospitalizations, reasons of hospitalization, deaths) were prospectively collected. The primary endpoint was the rate of hospitalization or death in a 28-day follow-up, whichever occurred first; subjects were censored at the day of last follow-up or up to 28 days. The Kaplan-Meier method was used to estimate the incidence rate curve in time. The Cox regression model was used to assess potential risk factors for unfavorable outcome. Results were shown as hazard ratio (HR) along with the corresponding 95 % Confidence Interval (95%CI). Results Among 1534 subjects (median [interquartile range, IQR] age 66.5 [52.4–74.9] years, 693 [45.2 %] women), 632 (41.2 %) received bamlanivimab ± etesevimab, 209 (13.6 %) casirivimab/imdevimab, 586 (38.2 %) sotrovimab, 107 (7.0 %) tixagevimab/cilgavimab. After 28-day follow-up, 87/1534 (5.6 %, 95%CI: 4.4%–6.8 %) met the primary outcome (85 hospitalizations, 2 deaths). Hospitalizations for COVID-19 (52, 3.4 %) occurred earlier than for other reasons (33, 2.1 %), after a median (IQR) of 3.5 (1–7) versus 8 (3–15) days (p = 0.006) from mAbs administration. In a multivariable Cox regression model, factors independently associated with increased hospitalization risk were age (hazard ratio [HR] 1.02, 95%CI 1.00–1.03, p = 0.021), immunodeficiency (HR 1.78, 95%CI 1.11–2.85, p = 0.017), pre-Omicron cale

Published
2024

7. Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness

Author

Monti, M, Benerini Gatta, L, Bugatti, M, Pezzali, I, Picinoli, S, Manfredi, M, Lavazza, A, Vanella, V, De Giorgis, V, Zanatta, L, Missale, F, Lonardi, S, Zanetti, B, Bozzoni, G, Cadei, M, Abate, A, Vergani, B, Balzarini, P, Battocchio, S, Facco, C, Turri-Zanoni, M, Castelnuovo, P, Nicolai, P, Fonsatti, E, Leone, B, Marengo, E, Sigala, S, Ronca, R, Perego, M, Lombardi, D, Vermi, W, Monti, Matilde, Benerini Gatta, Luisa, Bugatti, Mattia, Pezzali, Irene, Picinoli, Sara, Manfredi, Marcello, Lavazza, Antonio, Vanella, Virginia Vita, De Giorgis, Veronica, Zanatta, Lucia, Missale, Francesco, Lonardi, Silvia, Zanetti, Benedetta, Bozzoni, Giovanni, Cadei, Moris, Abate, Andrea, Vergani, Barbara, Balzarini, Piera, Battocchio, Simonetta, Facco, Carla, Turri-Zanoni, Mario, Castelnuovo, Paolo, Nicolai, Piero, Fonsatti, Ester, Leone, Biagio Eugenio, Marengo, Emilio, Sigala, Sandra, Ronca, Roberto, Perego, Michela, Lombardi, Davide, Vermi, William, Monti, M, Benerini Gatta, L, Bugatti, M, Pezzali, I, Picinoli, S, Manfredi, M, Lavazza, A, Vanella, V, De Giorgis, V, Zanatta, L, Missale, F, Lonardi, S, Zanetti, B, Bozzoni, G, Cadei, M, Abate, A, Vergani, B, Balzarini, P, Battocchio, S, Facco, C, Turri-Zanoni, M, Castelnuovo, P, Nicolai, P, Fonsatti, E, Leone, B, Marengo, E, Sigala, S, Ronca, R, Perego, M, Lombardi, D, Vermi, W, Monti, Matilde, Benerini Gatta, Luisa, Bugatti, Mattia, Pezzali, Irene, Picinoli, Sara, Manfredi, Marcello, Lavazza, Antonio, Vanella, Virginia Vita, De Giorgis, Veronica, Zanatta, Lucia, Missale, Francesco, Lonardi, Silvia, Zanetti, Benedetta, Bozzoni, Giovanni, Cadei, Moris, Abate, Andrea, Vergani, Barbara, Balzarini, Piera, Battocchio, Simonetta, Facco, Carla, Turri-Zanoni, Mario, Castelnuovo, Paolo, Nicolai, Piero, Fonsatti, Ester, Leone, Biagio Eugenio, Marengo, Emilio, Sigala, Sandra, Ronca, Roberto, Perego, Michela, Lombardi, Davide, and Vermi, William

Abstract

Background: Mucosal Melanomas (MM) are highly aggressive neoplasms arising from mucosal melanocytes. Current treatments offer a limited survival benefit for patients with advanced MM; moreover, the lack of pre-clinical cellular systems has significantly limited the understanding of their immunobiology. Methods: Five novel cell lines were obtained from patient-derived biopsies of MM arising in the sino-nasal mucosa and designated as SN-MM1-5. The morphology, ultrastructure and melanocytic identity of SN-MM cell lines were validated by transmission electron microscopy and immunohistochemistry. Moreover, in vivo tumorigenicity of SN-MM1-5 was tested by subcutaneous injection in NOD/SCID mice. Molecular characterization of SN-MM cell lines was performed by a mass-spectrometry proteomic approach, and their sensitivity to PI3K chemical inhibitor LY294002 was validated by Akt activation, measured by pAkt(Ser473) and pAkt(Thr308) in immunoblots, and MTS assay. Results: This study reports the validation and functional characterization of five newly generated SN-MM cell lines. Compared to the normal counterpart, the proteomic profile of SN-MM is consistent with transformed melanocytes showing a heterogeneous degree of melanocytic differentiation and activation of cancer-related pathways. All SN-MM cell lines resulted tumorigenic in vivo and display recurrent structural variants according to aCGH analysis. Of relevance, the microscopic analysis of the corresponding xenotransplants allowed the identification of clusters of MITF-/CDH1-/CDH2 + /ZEB1 + /CD271 + cells, supporting the existence of melanoma-initiating cells also in MM, as confirmed in clinical samples. In vitro, SN-MM cell lines were sensitive to cisplatin, but not to temozolomide. Moreover, the proteomic analysis of SN-MM cell lines revealed that RICTOR, a subunit of mTORC2 complex, is the most significantly activated upstream regulator, suggesting a relevant role for the PI3K-Akt-mTOR pathway in these neoplasms. Co

Published
2024

10. Current management and future challenges in salivary glands cancer

Author

Locati, L, Ferrarotto, R, Licitra, L, Benazzo, M, Preda, L, Farina, D, Gatta, G, Lombardi, D, Nicolai, P, Vander Poorten, V, Chua, M, Vischioni, B, Sanguineti, G, Morbini, P, Fonseca, I, Sozzi, D, Merlotti, A, Orlandi, E, Locati, L, Ferrarotto, R, Licitra, L, Benazzo, M, Preda, L, Farina, D, Gatta, G, Lombardi, D, Nicolai, P, Vander Poorten, V, Chua, M, Vischioni, B, Sanguineti, G, Morbini, P, Fonseca, I, Sozzi, D, Merlotti, A, and Orlandi, E

Abstract

Salivary gland cancers (SGCs) are rare, accounting for less than 5% of all malignancies of the head and neck region, and are morphologically heterogeneous. The diagnosis is mainly based on histology, with the complementary aid of molecular profiling, which is helpful in recognizing some poorly differentiated, borderline, or atypical lesions. Instrumental imaging defines the diagnosis, representing a remarkable tool in the treatment plan. Ultrasound and magnetic resonance are the most common procedures used to describe the primary tumour. The treatment of SGCs is multimodal and consists of surgery, radiotherapy, and systemic therapy; each treatment plan is, however, featured on the patient and disease’s characteristics. On 24 June 2022, in the meeting “Current management and future challenges in salivary gland cancers” many experts in this field discussed the state of the art of SGCs research, the future challenges and developments. After the meeting, the same pool of experts maintained close contact to keep these data further updated in the conference proceedings presented here. This review collects the insights and suggestions that emerged from the discussion during and after the meeting per se.

Published
2023

12. ROXA SMITH

Author

Lombardi, D. Dominick

Subjects
Painting, Modern -- Exhibitions -- Criticism and interpretation, Arts, visual and performing
Abstract

No Vacancy C24 Gallery, New York March 23-May 11, 2023 No Vacancy, the current exhibition at C24 gallery, takes some time to appreciate since there are no visible inhabitants in [...]

Published
2023

13. NNLO QCD Berechnungen verbunden mit Partonenschauer für Vektorbosonpaarproduktion mittels MiNNLOPS

Author

Lombardi, D., Weiler, Andreas (Prof. Dr.), and Zanderighi, Giulia (Prof. Dr.)

Subjects
Physik, ddc:530
Abstract

The MiNNLOPS method allows to reach NNLO QCD accuracy for physics observables inclusive over QCD radiation and to properly interface them to parton showers. We apply this algorithm to diboson production processes, which are of fundamental importance in the LHC research programme. In particular, we report results for Zγ production, as well as for W+W− and ZZ production. Die MiNNLOPS Methode erlaubt es NNLO Genauigkeit in QCD für physikalische Observablen zu erreichen, welche inklusiv bezüglich QCD Strahlung sind, und diese Vorhersagen mit den Partonenschauer zu verbinden. Dieser Algorithmus wird auf die Vektorbosonpaarproduktion angewendet, welche von fundamentaler Bedeutung für das LHC-Forschungsprogramm ist. Insbesondere werden Vorhersagen für die Produktion von Zγ Ereignissen, sowie von W+W− und ZZ Ereignissen berechnet.

Published
2022

14. Adjuvant radiotherapy and radioiodine treatment for locally advanced differentiated thyroid cancer: systematic review and meta-analysis

Author

Dicuonzo, S, Pedretti, S, Mangoni, M, Monari, F, Fanetti, G, Borsatti, E, Lombardi, D, Vianello, F, Iacobone, M, Corvo, R, Magrini, S, Pappagallo, G, Arcangeli, S, D'Angelillo, R, Dicuonzo S., Pedretti S., Mangoni M., Monari F., Fanetti G., Borsatti E., Lombardi D., Vianello F., Iacobone M., Corvo R., Magrini S. M., Pappagallo G., Arcangeli S., D'Angelillo R. M., Dicuonzo, S, Pedretti, S, Mangoni, M, Monari, F, Fanetti, G, Borsatti, E, Lombardi, D, Vianello, F, Iacobone, M, Corvo, R, Magrini, S, Pappagallo, G, Arcangeli, S, D'Angelillo, R, Dicuonzo S., Pedretti S., Mangoni M., Monari F., Fanetti G., Borsatti E., Lombardi D., Vianello F., Iacobone M., Corvo R., Magrini S. M., Pappagallo G., Arcangeli S., and D'Angelillo R. M.

Abstract

Background: Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated. Methods: The panel of the Italian Association of Radiotherapy and Clinical Oncology developed a clinical recommendation on the addition of EBRT to radioiodine after surgery for locally advanced differentiated thyroid cancer by using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the Evidence to Decision framework. A systematic review with meta-analysis about this topic was conducted with a focus on outcome of benefits and toxicity. Results: Locoregional control was improved by EBRT while no considerable toxicity impact was reported. Conclusion: The panel judged uncertain the benefit/harms balance; final recommendation was conditional both for EBRT + radioiodine and radioiodine alone in the adjuvant setting.

Published
2021

16. Benchmarking sustainability in cities: The role of indicators and future scenarios

Author

Boyko, Christopher T., Gaterell, Mark R., Barber, Austin R.G., Brown, Julie, Bryson, John R., Butler, David, Caputo, Silvio, Caserio, Maria, Coles, Richard, Cooper, Rachel, Davies, Gemma, Farmani, Raziyeh, Hale, James, Hales, A. Chantal, Hewitt, C. Nicholas, Hunt, Dexter V.L., Jankovic, Lubo, Jefferson, Ian, Leach, Joanne M., Lombardi, D. Rachel, MacKenzie, A. Robert, Memon, Fayyaz A., Pugh, Thomas A.M., Sadler, John P., Weingaertner, Carina, Whyatt, J. Duncan, and Rogers, Christopher D.F.

Published
2012
Full Text
View/download PDF

17. ALLIE MCGHEE

Author

Lombardi, D. Dominick

Subjects
Painting, Modern -- Exhibitions -- Criticism and interpretation, Arts, visual and performing
Abstract

Parallax Harper's Chelsea 512, New York September 8-October 22,2022 Throughout this exhibition, the art of Allie McGhee evokes such a youthful and uncompromising focus on variations in scale, texture, technique, [...]

Published
2022

18. ZZ production at nNNLO plus PS with MINNLOPS

Author

Buonocore, L, Koole, G, Lombardi, D, Rottoli, L, Wiesemann, M, Zanderighi, G, Buonocore, L, Koole, G, Lombardi, D, Rottoli, L, Wiesemann, M, and Zanderighi, G

Abstract

We consider ZZ production in hadronic collisions and present state-of-the-art predictions in QCD perturbation theory matched to parton showers. Next-to-next-to-leading order corrections to the quark-initiated channel are combined with parton showers using the MiNNLOPS method, while next-to-leading order corrections to the loop-induced gluon fusion channel are matched using the Powheg method. Their combination, dubbed nNNLO+PS, constitutes the best theoretical description of ZZ events to date. Spin correlations, interferences and off-shell effects are included by calculating the full process pp → l+l−l(′)+l(′)−. We show the crucial impact of higher-order corrections for both quark- and gluon-initiated processes as well as the relevance of the parton shower in certain kinematical regimes. Our predictions are in very good agreement with recent LHC data.

Published
2022

19. Novel Multidisciplinary Salivary Gland Society (MSGS) Questionnaire: An International Consensus.

Author

Buchholzer, S, Faure, F, Tcheremissinoff, L, Herrmann, FR, Lombardi, T, Ng, S-K, Lopez, J-M, Borner, U, Witt, RL, Irvine, R, Abboud, O, Cernea, CR, Ghan, S, Matsunobu, T, Ahmad, Z, Morton, R, Anicin, A, Magdy, EA, Al Abri, R, Konstantinidis, I, Capaccio, P, Klein, H, Poorten, VV, Lombardi, D, Lyons, B, Al Rand, H, Liao, G, Kim, JK, Subha, S, Su, RY-X, Su, C-H, Boselie, F, Andre, R, Seebach, JD, Marchal, F, Buchholzer, S, Faure, F, Tcheremissinoff, L, Herrmann, FR, Lombardi, T, Ng, S-K, Lopez, J-M, Borner, U, Witt, RL, Irvine, R, Abboud, O, Cernea, CR, Ghan, S, Matsunobu, T, Ahmad, Z, Morton, R, Anicin, A, Magdy, EA, Al Abri, R, Konstantinidis, I, Capaccio, P, Klein, H, Poorten, VV, Lombardi, D, Lyons, B, Al Rand, H, Liao, G, Kim, JK, Subha, S, Su, RY-X, Su, C-H, Boselie, F, Andre, R, Seebach, JD, and Marchal, F

Abstract

OBJECTIVES: First, establishment and validation of a novel questionnaire documenting the burden of xerostomia and sialadenitis symptoms, including quality of life. Second, to compare two versions regarding the answering scale (proposed developed answers Q3 vs. 0-10 visual analogue scale Q10) of our newly developed questionnaire, in order to evaluate their comprehension by patients and their reproducibility in time. STUDY DESIGN: The study is a systematic review regarding the evaluation of the existing questionnaire and a cohort study regarding the validation of our new MSGS questionnaire. MATERIALS AND METHODS: A Multidisciplinary Salivary Gland Society (MSGS) questionnaire consisting of 20 questions and two scoring systems was developed to quantify symptoms of dry mouth and sialadenitis. Validation of the questionnaire was carried out on 199 patients with salivary pathologies (digestive, nasal, or age-related xerostomia, post radiation therapy, post radioiodine therapy, Sjögren's syndrome, IgG4 disease, recurrent juvenile parotitis, stones, and strictures) and a control group of 66 healthy volunteers. The coherence of the questionnaire's items, its reliability to distinguish patients from healthy volunteers, its comparison with unstimulated sialometry, and the time to fill both versions were assessed. RESULTS: The novel MSGS questionnaire showed good internal coherence of the items, indicating its pertinence: the scale reliability coefficients amounted to a Cronbach's alpha of 0.92 for Q10 and 0.90 for Q3. The time to complete Q3 and Q10 amounted, respectively, to 5.23 min (±2.3 min) and 5.65 min (±2.64 min) for patients and to 3.94 min (±3.94 min) and 3.75 min (±2.11 min) for healthy volunteers. The difference between Q3 and Q10 was not significant. CONCLUSION: We present a novel self-administered questionnaire quantifying xerostomia and non-tumoral salivary gland pathologies. We recommend the use of the Q10 version, as its scale type is well known in the literatu

Published
2022

23. ROY DOWELL

Author

Lombardi, D. Dominick

Subjects
Painting, Modern -- Exhibitions -- Criticism and interpretation, Arts, visual and performing
Abstract

Miles McEnery, New York February 3-March 12,2022 The first thing visitors may notice about Roy Dowell's paintings is the mystical aspect of the work--the ritualistic nature of the forms, even [...]

Published
2022

26. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Author

Lorusso, D, Ferrandina, G, Colombo, N, Pignata, S, Pietragalla, A, Sonetto, C, Pisano, C, Lapresa, M, Savarese, A, Tagliaferri, P, Lombardi, D, Cinieri, S, Breda, E, Sabatucci, I, Sabbatini, R, Conte, C, Cecere, S, Maltese, G, Scambia, G, Lorusso D., Ferrandina G., Colombo N., Pignata S., Pietragalla A., Sonetto C., Pisano C., Lapresa M. T., Savarese A., Tagliaferri P., Lombardi D., Cinieri S., Breda E., Sabatucci I., Sabbatini R., Conte C., Cecere S. C., Maltese G., Scambia G., Lorusso, D, Ferrandina, G, Colombo, N, Pignata, S, Pietragalla, A, Sonetto, C, Pisano, C, Lapresa, M, Savarese, A, Tagliaferri, P, Lombardi, D, Cinieri, S, Breda, E, Sabatucci, I, Sabbatini, R, Conte, C, Cecere, S, Maltese, G, Scambia, G, Lorusso D., Ferrandina G., Colombo N., Pignata S., Pietragalla A., Sonetto C., Pisano C., Lapresa M. T., Savarese A., Tagliaferri P., Lombardi D., Cinieri S., Breda E., Sabatucci I., Sabbatini R., Conte C., Cecere S. C., Maltese G., and Scambia G.

Abstract

Objective: Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical data reported Bevacizumab effectiveness in EC both as single agent and in combination with chemotherapy. Methods: In a phase II trial, patients with advanced (FIGO stage III-IV) or recurrent EC were randomized to receive Carboplatin-Paclitaxel standard dose for 6–8 cycles vs Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy and maintenance until disease progression or unacceptable toxicity. The primary endpoint was progression free survival (PFS). Results: 108 patients were randomized; PFS (10.5 vs 13.7 months, HR 0.84 p = 0.43), overall response rate (ORR 53.1% vs 74.4%) and overall survival (OS) (29.7 vs 40.0 months, HR 0.71 p = 0.24) resulted in a non-significant increase in Bevacizumab treated patients. The PFS increase became significant when an exploratory analysis with the Breslow test was used. Moreover, patients treated with Bevacizumab experienced a significant increase in 6-month disease control rate (70.4% vs 90.7%). Cardiovascular events were more frequent in the experimental arm (“de novo” grade ≥2 hypertension 21% vs 0% and grade ≥2 thromboembolic events 11% vs 2% in the Bevacizumab vs standard treatment arm, respectively). Conclusions: Bevacizumab combined with chemotherapy in the treatment of advanced/recurrent EC failed to demonstrate a significant increase in PFS in the MITO END-2 trial. Nevertheless, these preliminary data suggests some effectiveness of the antiangiogenic agent which merits further exploration in a larger population with a better molecular characterization.

Published
2019

28. Advancing MiNNLOPS to diboson processes: Zγ production at NNLO+PS

Author

Lombardi, D., Wiesemann, M., and Zanderighi, G.

Subjects
Nuclear Theory
Abstract

We consider $Z \gamma$ production in hadronic collisions and present the first computation of next-to-next-to-leading order accurate predictions consistently matched to parton showers (NNLO+PS). Spin correlations, interferences and off-shell effects are included by calculating the full process $pp\to\ell^+\ell^-\gamma$. We extend the recently developed MiNNLO$_{\rm PS}$ method to genuine $2\to 2$ hard scattering processes at the LHC, which paves the way for NNLO+PS simulations of all diboson processes. This is the first $2\to2$ NNLO+PS calculation that does not require an a-posteriori multi-differential reweighting. We find that both NNLO corrections and matching to parton showers are crucial for an accurate simulation of the $Z \gamma$ process. Our predictions are in very good agreement with recent ATLAS data.

Published
2021

29. 842P Carboplatin-induced thrombocytopenia in ovarian cancer: A focus on predictive factors

Author

Mazzeo, R., primary, Bartoletti, M., additional, de Scordilli, M., additional, Alberti, M., additional, Michelotti, A., additional, Lisanti, C., additional, Parnofiello, A., additional, Bertoli, E., additional, Buriolla, S., additional, Pelizzari, G., additional, Cortiula, F., additional, Basile, D., additional, Gagno, S., additional, Scalone, S., additional, Nicoloso, M.S., additional, Corsetti, S., additional, Lombardi, D., additional, Gerratana, L., additional, Sorio, R., additional, and Puglisi, F., additional

Published
2020
Full Text
View/download PDF

30. 963P Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma

Author

Lorini, L., primary, Gurizzan, C., additional, Tomasoni, M., additional, Lombardi, D., additional, Mattavelli, D., additional, Paderno, A., additional, Deganello, A., additional, Ardighieri, L., additional, Battocchio, S., additional, Bozzola, A., additional, Ravanelli, M., additional, Maddalo, M., additional, Zamparini, M., additional, Magrini, S.M., additional, Maroldi, R., additional, Nicolai, P., additional, Berruti, A., additional, and Bossi, P., additional

Published
2020
Full Text
View/download PDF

32. Clinical and histological prognostic factors of recurrent and/or metastatic salivary gland adenoid cystic carcinoma

Author

Lorini, L., Gurizzan, C., Tomasoni, M., Lombardi, D., Mattavelli, D., Paderno, A., Deganello, A., Ardighieri, L., Battocchio, S., Bozzola, A., Ravanelli, M., Maddalo, M., Zamparini, M., Magrini, S. M., Maroldi, R., Nicolai, P., Berruti, A., and Bossi, P.

Subjects
skin and connective tissue diseases, digestive system, neoplasms, biological factors, digestive system diseases
Published
2020

36. How a growth mindset can change the climate: The power of implicit beliefs in influencing people's view and action

Author

Duchi, L. (Lorenzo), Lombardi, D. (Doug), Paas, G.W.C. (Fred), Loyens, S.M.M. (Sofie), Duchi, L. (Lorenzo), Lombardi, D. (Doug), Paas, G.W.C. (Fred), and Loyens, S.M.M. (Sofie)

Abstract

Although people seem to be concerned about climate change, few are pro-actively engaged in attempting to mitigate it. This discrepancy between environmental view and action has been recognized as a great challenge. This empirical study examined that disparity by investigating people's mindsets about the world. Such mindsets concern the degree to which people perceive their world as a

Published
2020
Full Text
View/download PDF

50. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Author

Lorusso, Domenica, Ferrandina, Maria Gabriella, Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M. T., Savarese, A., Tagliaferri, P., Lombardi, Debora Benedetta, Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S. C., Maltese, G., Scambia, Giovanni, Lorusso D., Ferrandina G. (ORCID:0000-0003-4672-4197), Lombardi D., Scambia G. (ORCID:0000-0003-2758-1063), Lorusso, Domenica, Ferrandina, Maria Gabriella, Colombo, N., Pignata, S., Pietragalla, A., Sonetto, C., Pisano, C., Lapresa, M. T., Savarese, A., Tagliaferri, P., Lombardi, Debora Benedetta, Cinieri, S., Breda, E., Sabatucci, I., Sabbatini, R., Conte, C., Cecere, S. C., Maltese, G., Scambia, Giovanni, Lorusso D., Ferrandina G. (ORCID:0000-0003-4672-4197), Lombardi D., and Scambia G. (ORCID:0000-0003-2758-1063)

Abstract

Objective: Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical data reported Bevacizumab effectiveness in EC both as single agent and in combination with chemotherapy. Methods: In a phase II trial, patients with advanced (FIGO stage III-IV) or recurrent EC were randomized to receive Carboplatin-Paclitaxel standard dose for 6–8 cycles vs Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy and maintenance until disease progression or unacceptable toxicity. The primary endpoint was progression free survival (PFS). Results: 108 patients were randomized; PFS (10.5 vs 13.7 months, HR 0.84 p = 0.43), overall response rate (ORR 53.1% vs 74.4%) and overall survival (OS) (29.7 vs 40.0 months, HR 0.71 p = 0.24) resulted in a non-significant increase in Bevacizumab treated patients. The PFS increase became significant when an exploratory analysis with the Breslow test was used. Moreover, patients treated with Bevacizumab experienced a significant increase in 6-month disease control rate (70.4% vs 90.7%). Cardiovascular events were more frequent in the experimental arm (“de novo” grade ≥2 hypertension 21% vs 0% and grade ≥2 thromboembolic events 11% vs 2% in the Bevacizumab vs standard treatment arm, respectively). Conclusions: Bevacizumab combined with chemotherapy in the treatment of advanced/recurrent EC failed to demonstrate a significant increase in PFS in the MITO END-2 trial. Nevertheless, these preliminary data suggests some effectiveness of the antiangiogenic agent which merits further exploration in a larger population with a better molecular characterization.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results